3P Biopharmaceuticals and Buzzard Pharmaceuticals start a cGMP manufacturing collaboration to develop a new treatment to combat solid tumours

3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for cGMP manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard Pharmaceuticals, a Swedish pharmaceutical company developing and re-positioning drugs in oncology.

Buzzard and 3P began their collaboration at the end of last year when 3P was selected as the cGMP manufacturing partner for Buzzard’s oncology drug Isunakinra. This molecule was previously developed for eye indications but based on a strong scientific rationale for IL-1 inhibition in cancer treatment Buzzard is re-positioning the drug for cancer indications. A phase I/II clinical trial in solid tumor patients was initiated at the Baylor Research Institute in Dallas (Texas) in 2020.

3P Bio cGMP manufacturing partners with Buzzard Pharmaceuticals.

Cytokines are small proteins that are crucial in controlling the growth and activity of immune cells and blood cells. There are different kinds of cytokines, and interleukin-1 (IL-1) is one of the most important. Chronic inflammation mediated by IL-1 signaling leads to tumor immune suppression, triggers suppression of adaptive immunity, tumour promotion, and metastasis. Isunakinra is a recombinant protein that potently inhibits signaling of both IL-1 alpha and IL-1 beta through the IL-1 receptor. Based on these functions for IL-1 in the tumor micro-environment, Isunakinra is being studied in cancer indications.

Dámaso Molero, CEO at 3P Biopharmaceuticals added: “We are pleased to be a part of this project aimed at combatting the cancer, this multifactorial global disease. We are going to collaborate to provide more opportunities to cancer suffering patients.”

Maarten de Château, CEO at Buzzard Pharmaceuticals added: “We are very pleased to work with 3P Bio on our exciting recombinant protein project, including production of GMP material for our planned expansion study in solid tumor patients. We find that 3P Bio has a very professional approach and flexible way of working with our project.”

Our dedicated team of specialists will be happy to discuss any of your cGMP manufacturing needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.